| Not Yet Recruiting | [¹⁴C] Hydronidone Mass Balance Study Chronic Hepatitis B-related Liver Fibrosis | Phase 1 | 2026-04-30 |
| Recruiting | A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cir Chronic Hepatitis B With Hepatic Fibrosis | Phase 3 | 2026-03-16 |
| Not Yet Recruiting | A Study of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver Fibrosis Chronic Hepatitis B-related Liver Fibrosis | Phase 2 | 2026-03-15 |
| Recruiting | A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver Fibrosis Chronic Hepatitis B With Hepatic Fibrosis | Phase 2 | 2026-03-12 |
| Not Yet Recruiting | Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia Radiation-induced Lung Injury, Immune-related Pneumonia | Phase 2 / Phase 3 | 2026-02-28 |
| Not Yet Recruiting | Study of Hydroxynidone Capsules in Patients With Hepatic Impairment and Matched Healthy Controls Liver Fibrosis | Phase 1 | 2026-02-15 |
| Not Yet Recruiting | A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Liver Fibrosis, Liver Fibrosis in Chronic Hepatitis B | Phase 3 | 2026-01-30 |
| Completed | QTc Assessment in a Single-Dose Study of Hydronidone Capsules Hepatic Fibrosis | Phase 1 | 2025-12-31 |
| Not Yet Recruiting | Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafen Chronic Hepatitis B Liver Fibrosis, DDI (Drug-Drug Interaction) | Phase 1 | 2025-12-30 |
| Recruiting | A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency Renal Insufficiency Chronic | Phase 1 | 2025-12-25 |
| Not Yet Recruiting | The Phase Ⅰd Clinical Trial of Hydronidone Capsules Liver Fibrosis | Phase 1 | 2025-12-05 |
| Recruiting | Preliminary Human Trials of F230 Tablets Pulmonary Hypertension | Phase 1 | 2025-05-15 |
| Recruiting | Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis Liver Fibrosis | Phase 3 | 2023-08-12 |
| Recruiting | F573 for Injection for the Treatment of Liver Injury/Failure Acute Liver Failure, Acute-On-Chronic Liver Failure | Phase 2 | 2023-03-24 |
| Recruiting | Efficacy and Safety of Pirfenidone Capsules in the Treatment of Pneumoconiosis Pneumoconiosis | Phase 3 | 2022-06-07 |
| Completed | Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial. Liver Fibrosis | Phase 3 | 2021-12-30 |
| Completed | F573 Ia Clinical Trial Tolerance, Pharmacokinetic | Phase 1 | 2021-02-08 |
| Completed | Study on Pharmacokinetics of Hydronidone Pharmacokinetics of Hydronidone | Phase 1 | 2019-10-30 |
| Completed | Study on PK of Hydronidone in Patients and Special Population Hepatitis b & Liver Dysfunction | Phase 1 | 2019-09-03 |
| Unknown | Pirfenidone Capsule in Patients With Chronic Kidney Disease G2 and G3a Study on Safety and Pharmacokinetics Renal Insufficiency | Phase 1 | 2019-08-27 |
| Completed | A Study About Safety and Efficacy of Pirfenidone to Treat Grade 2 or Grade3 Radiation-induced Lung Injury. Radiation-induced Lung Injury | Phase 2 | 2019-05-24 |
| Completed | Pharmacokinetic Interactions Between Hydronidone and Entecavir Capsules in Healthy Chinese Subjects Hydronidone | Phase 1 | 2019-05-15 |
| Completed | Study on Hydronidone Capsule BE Healthy | N/A | 2019-01-16 |
| Unknown | Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease Systemic Sclerosis-associated Interstitial Lung Disease (Ssc-ild) | Phase 3 | 2018-06-15 |
| Unknown | Efficacy and Safety of Pirfenidone in Patient With Dermatomyositis Interstitial Lung Disease (Dm-ILD) Dermatomyositis Interstitial Lung Disease (Dm-ILD) | Phase 3 | 2018-06-05 |
| Unknown | Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung Injury Radiation Pneumonitis | Phase 2 | 2015-01-01 |